Lemaitre, F., Chakrama, F., O'Grady, T., Peulen, O., Rademaker, G., Deward, A., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F., & Habraken, Y. (30 May 2023). The transcription factor c-Jun mediates specific reprogramming of pre-mRNA splicing during platinum-based therapy via RBM39 [Poster presentation]. 28th Annual International Conference of the RNA society RNA 2023, Singapore. |
Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F.* , & Habraken, Y.*. (02 February 2023). The transcription factor c-Jun mediates specific reprogramming of pre-mRNA splicing during platinum-based therapy via RBM39 [Poster presentation]. séminaire des chercheurs Télévie 2023. * These authors have contributed equally to this work. |
Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Peulen, O., Rademaker, G., Deward, A., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F.* , & Habraken, Y.*. (09 December 2022). The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress. Nucleic Acids Research, 50 (22), 12768 - 12789. doi:10.1093/nar/gkac1130 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F.* , & Habraken, Y.*. (09 September 2022). The transcription factor c-Jun inhibits RBM39 to reprogram mRNA splicing during genotoxic stress [Poster presentation]. Interuniversity PhD student day. * These authors have contributed equally to this work. |
Lemaitre, F.* , Chakrama, F.* , O'Grady, T., Dequiedt, F.* , & Habraken, Y.*. (08 April 2022). c-Jun directly controls spliceosome specificity through RBM39 binding in response to genotoxic chemotherapy [Poster presentation]. séminaire des chercheurs Télévie 2022. * These authors have contributed equally to this work. |
Lemaitre, F.* , Chakrama, F.* , Dequiedt, F.* , & Habraken, Y.*. (17 March 2022). c-Jun directly controls spliceosome specificity through RBM39 binding in response to genotoxic chemotherapy [Poster presentation]. Multiple facets of RNA in development and disease. * These authors have contributed equally to this work. |
Lemaitre, F., Chakrama, F., O'Grady, T., Chabot, B., Piette, J., Colige, A., Lambert, C., Dequiedt, F., & Habraken, Y. (March 2022). The transcription factor c-Jun inhibits RBM39 to reprogram pre-mRNA splicing during genotoxic stress [Poster presentation]. THE MULTIPLE FACETS OF RNA IN DEVELOPMENT AND DISEASE, Nice, France. |
Gamelas, S., Moura, N., Habraken, Y., Piette, J., Neves, M., & Faustino, M. (September 2021). Tetracationic porphyrin derivatives against human breast cancer. Journal of Photochemistry and Photobiology B: Biology, 222, 112258. doi:10.1016/j.jphotobiol.2021.112258 Peer Reviewed verified by ORBi |
Habraken, Y. (July 2021). Large scale regulation of the spliceosome through direct binding of c-JUN to RBM39 following genotoxic stress [Paper presentation]. 4th International Caparica Conference in SPLICING 2021, Caparica, Portugal. |
Lemaitre, F., Chakrama, F., Dequiedt, F., Chabot, B., Klinck, R., Colige, A., Piette, J., Lambert, C., & Habraken, Y. (15 April 2021). c-Jun and RBM39 co-regulate alternative splicing induced by chemotherapy compounds [Poster presentation]. Joint Course on Post-Transcriptional Gene Regulation and Genome Instability, Paris, France. |
Chakramah, F., Lemaitre, F., Dequiedt, F., Chabot, B., Klink, R., Colige, A., Piette, J., Lambert, C., & Habraken, Y. (July 2020). c-Jun and RBM39 co-regulate alternative splicing induced by chemotherapy compounds [Poster presentation]. Third international Caparica conference in splicing, Caparica, Portugal. |
Shostak, K., Jiang, Z., CHARLOTEAUX, B., Mayer, A., Habraken, Y., Tharun, L., Klein, S., Xu, X., Duong, H. Q., Vislovukh, A., Close, P., Florin, A., Rambow, F., Marine, J.-C., Büttner, R., & Chariot, A. (09 March 2020). The X-linked trichothiodystrophy-causing gene RNF113A links the spliceosome to cell survival upon DNA damage. Nature Communications, 11 (1). doi:10.1038/s41467-020-15003-7 Peer Reviewed verified by ORBi |
Gianfrancesco, M., Dehairs, J., L'homme, L., Herinckxe, G., Esser, N., Jansen, O., Habraken, Y., Lassence, C., Swinnen, J., Rider, M., Piette, J., PAQUOT, N., & Legrand, S. (April 2019). Saturated fatty acids induce NLRP3 activation in human macrophages through K+ efflux resulting from phospholipid saturation and Na, K-ATPase disruption. BBA - Molecular and Cell Biology of Lipids, 1864, 1017–1030. doi:10.1016/j.bbalip.2019.04.001 Peer reviewed |
Rademaker, G., Costanza, B., Bellier, J., Herfs, M., Peiffer, R., Agirman, F., Maloujahmoum, N., Habraken, Y., Delvenne, P., Bellahcene, A., Castronovo, V.* , & Peulen, O.*. (2019). Human colon cancer cells highly express myoferlin to maintain a fit mitochondrial network and escape p53-driven apoptosis. Oncogenesis. doi:10.1038/s41389-019-0130-6 Peer Reviewed verified by ORBi * These authors have contributed equally to this work. |
Chakrama, F., Gabriel, M., Deward, A., Lassence, C., Colige, A., Lambert, C., & Habraken, Y. (September 2018). Alternative splicing induced by Cisplatin: effect on the shape of mitochondria [Poster presentation]. Joint meeting GIGA-Cancer Day 2018 / EDT-Cancerology. |
Trussart, C., Pirlot, C., Di Valentin, E., Piette, J., & Habraken, Y. (2018). Melanoma antigen-D2 controls cell cycle progression and modulates the DNA damage response. Biochemical Pharmacology. doi:10.1016/j.bcp.2018.01.035 Peer Reviewed verified by ORBi |
Chakrama, F., Lambert, C., Gabriel, M., Deward, A., Lassence, C., Colige, A., & Habraken, Y. (October 2017). Alternative splicing induced by cisplatin : Effect on mitochondria shape [Poster presentation]. Forty Years of mRNA Splicing: From Discovery to Therapeutics meeting, New-York, United States. |
Trussart, C., Pirlot, C., Piette, J., & Habraken, Y. (11 May 2017). MAGED2 function as cell cycle regulator after a genotoxic stress [Poster presentation]. PhD DAY. |
Gabriel, M., Garbacki, N., Chakrama, F., Habraken, Y., Colige, A., & Lambert, C. (May 2017). Chemotherapy regulates the expression of alternative transcripts: relationship to the new hallmarks of cancer and therapeutic efficacy [Poster presentation]. International symposium on the Hallmarks of Cancer: Focus on RNA, Prague, Czechia. |
Habraken, Y. (2017). Les dommages à l’ADN et leurs réponses cellulaires [Paper presentation]. Exposé pour la section science et nature de l'université du troisième âge. |
Trussart, C., Pirlot, C., Piette, J., & Habraken, Y. (2017). Incidence of MAGED2 on cell cycle after a camptothecin treatment [Poster presentation]. GIGA DAY 2017. |
Deward, A., Gabriel, M., Klinck, R., Chabot, B., Figueroa, M., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (11 September 2016). c-Jun regulates altered pre-mRNA splicing in response to cisplatin [Poster presentation]. Splicing 2016, Caparica, Portugal. |
Henry, A., Nokin, M.-J., Leroi, N., Lallemand, F., Lambert, J., Goffart, N., RONCARATI, P., BIANCHI, E., Peixoto, P., Blomme, A., Turtoi, A., Peulen, O., Habraken, Y., Scholtes, F., Martinive, P., Delvenne, P., Rogister, B., Castronovo, V., & Bellahcene, A. (2016). New role of osteopontin in DNA repair and impact on human glioblastoma radiosensitivity. Oncotarget. doi:10.18632/oncotarget.11483 Peer Reviewed verified by ORBi |
Henry, A., Nokin, M.-J., Leroi, N., LALLEMAND, F., Lambert, J., Goffart, N., Peixoto, P., Blomme, A., BIANCHI, E., Habraken, Y., RONCARATI, P., Peulen, O., SCHOLTES, F., MARTINIVE, P., Rogister, B., Delvenne, P., Turtoi, A., Castronovo, V., & Bellahcene, A. (22 March 2016). Osteopontin predicts radiotherapy response of glioblastoma patients : new role in DNA damage repair [Paper presentation]. 3rd Symposium on small animal precision image-guided radiotherapy, Gand, Belgium. |
Deward, A., Gabriel, M., Klinck, R., Chabot, B., Figueroa, M., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (25 January 2016). A c-jun/splicing factors complex triggers altered pre-mRNA splcing in response to cisplatin [Poster presentation]. GIGA DAY Molecular Biology of Disease. |
Pirlot, C., Thiry, M., Trussart, C., Di Valentin, E., Piette, J., & Habraken, Y. (2016). Melanoma antigen-D2: a nucleolar protein undergoing delocalization during cell cycle and after cellular stress. Biochimica et Biophysica Acta. Molecular Cell Research, 1853 (3), 581-595. doi:10.1016/j.bbamcr.2015.12.010 Peer Reviewed verified by ORBi |
Trussart, C., Pirlot, C., Piette, J., & Habraken, Y. (03 December 2015). Melanoma AntiGEn D2 : a new cell cycle regulator of the DNA Damage Response network [Poster presentation]. Séminaire des chercheurs télévie. |
Pirlot, C., Thiry, M., Trussart, C., Di Valentin, E., Piette, J., & Habraken, Y. (03 November 2015). Melanoma antigen D2, a substrate of ATM, is a nucleolar protein that shuttles with cell cycle and cellular stress [Poster presentation]. PI3K-like protein kinases, Milan, Italy. |
Deward, A., Gabriel, M., Delforge, Y., Chabot, B., Klinck, R., Figueroa, M., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (28 September 2015). c-Jun : a new regulatory element for cisplatin induced alternative splicing [Poster presentation]. Discoble meeting IAP 7/32, Gent, Belgium. |
Pirlot, C., Thiry, M., Trussart, C., Piette, J., & Habraken, Y. (28 September 2015). Melanoma AntiGEn D2 : a new nucleolar protein undergoing delocalization during cell cycle and after cellular stress [Poster presentation]. IAP meeting, Gent, Belgium. |
Henry, A., Bellahcene, A., Castronovo, V., Peixoto, P., Goffart, N., Lallemand, F., Leroi, N., Peulen, O., MARTINIVE, P., Habraken, Y., Turtoi, A., Rogister, B., & Blomme, A. (Other coll.). (10 September 2015). Osteopontin as a new target in glioblastoma progression and resistance to radiotherapy [Paper presentation]. II International Symposium on clinical and basic investigation in glioblastoma, Toledo, Spain. |
Trussart, C., Orban, T., Di Valentin, E., Piette, J., & Habraken, Y. (06 February 2015). The phosphorylation of RelA on Ser547 does not modulate NF-kB activation after TNFa treatment like after a genotoxic stress [Poster presentation]. DISCOLBEL meeting in KUL, Louvain, Belgium. |
Pirlot, C., Thiry, M., Trussart, C., Piette, J., & Habraken, Y. (06 February 2015). Melanoma AntiGEn D2 (MAGED2): a new nucleolar protein undergoing re-localization after cellular stress [Poster presentation]. IAP meeting, Leuven, Belgium. |
Gabriel, M., Delforge, Y., Deward, A., Habraken, Y., Hennuy, B., Piette, J., Klinck, R., Chabot, B., Lambert, C., & Colige, A. (2015). Role of the splicing factor SRSF4 in cisplatin-induced modifications of pre-mRNA splicing and apoptosis. BMC Cancer, 15, 227. doi:10.1186/s12885-015-1259-0 Peer Reviewed verified by ORBi |
Trussart, C., Orban, T., Di Valentin, E., Piette, J., & Habraken, Y. (29 August 2014). Promoter specific regulation of NF-kappaB by RelA phosphorylation on Ser547 [Poster presentation]. Discobel meeting. |
Pirlot, C., Piette, J., & Habraken, Y. (January 2014). Melanoma AntiGEn D2 (MAGED2) a new partner of the DNA damage response? [Poster presentation]. Metabolism 2014: Alterations of metabolic pathways as therapeutic targets, Esch-sur-Alzette, Luxembourg. |
Trussart, C., Orban, T., Sabatel, H., Di Valentin, E., Piette, J., & Habraken, Y. (January 2014). Promotor specific regulation of NF-kappaB mediated transcription by the phosphorylation of p65 on Ser547 [Poster presentation]. Metabolism 2014: Alterations of metabolic pathways as therapeutic targets, Esh-sur-Alzette, Luxembourg. |
Deward, A., Gabriel, M., Delforge, Y., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (November 2013). Study of molecular mechanisms of DNA Damage induced alternative splicing: implications in cancer therapy [Poster presentation]. ICGEEB 2nd Post-EURASNET Symposium "RNA alternative Splicing", Trieste, Italy. |
Habraken, Y. (13 November 2012). An additional role for ATM in the control of NF-kappaB activation by DNA double-strand breaks [Paper presentation]. Molecular and Cellular Biology Meeting, Luxembourg, Luxembourg. |
Habraken, Y. (11 May 2012). NF-kappaB activation by DNA damage [Paper presentation]. Xème RÉUNION DU GROUPE DE CONTACT FNRS :Oxidative stress and genotoxic response, Mons, Belgium. |
Deward, A., Gabriel, M., Delforge, Y., Piette, J., Colige, A., Lambert, C., & Habraken, Y. (2012). Study of camptothecin- and cisplatin-induced alternative splicing events [Poster presentation]. Xème groupe de contact FNRS: oxidative stress and genotoxic responses, Mons, Belgium. |
Sabatel, H., Di Valentin, E., Gloire, G., Dequiedt, F., Piette, J., & Habraken, Y. (2012). Phosphorylation of p65(RelA) on Ser547 by ATM represses NF-κB-dependent transcription of specific genes after genotoxic stress. PLoS ONE. doi:10.1371/journal.pone.0038246 Peer Reviewed verified by ORBi |
Herfs, M., Hubert, P., POIRRIER, A.-L., Vandevenne, Renoux, V., Habraken, Y., Cataldo, D., Boniver, J., & Delvenne, P. (2012). Proinflammatory Cytokines Induce Bronchial Hyperplasia and Squamous Metaplasia in Smokers: Implications for chronic obstructive pulmonary disease therapy. American Journal of Respiratory Cell and Molecular Biology, 47 (1), 67-79. doi:10.1165/rcmb.2011-0353OC Peer Reviewed verified by ORBi |
Lecat, A., Di Valentin, E., Somja, J., Jourdan, S., Fillet, M., Kufer, T., Habraken, Y., Sadzot-Delvaux, C., Louis, E., Delvenne, P., Piette, J., & Legrand-Poels, S. (2012). The c-jun N-terminal Kinase (JNK)-binding Protein (JNKBP1) Acts as a Negative Regulator of NOD2 Protein Signaling by Inhibiting Its Oligomerization Process. Journal of Biological Chemistry, 287 (35), 29213-26. doi:10.1074/jbc.M112.355545 Peer Reviewed verified by ORBi |
Sabatel, H., Pirlot, C., Piette, J., & Habraken, Y. (November 2011). Importance of the PIKKs in NF-kappaB activation by genotoxic stress. Biochemical Pharmacology, 82 (10), 1371-83. doi:10.1016/j.bcp.2011.07.105 Peer Reviewed verified by ORBi |
Coupienne, I., Bontems, S., Dewaele, M., Rubio, N., Habraken, Y., Fulda, S., Agostinis, P., & Piette, J. (2011). NF-kappaB inhibition improves the sensitivity of human glioblastoma cells to 5-aminolevulinic acid-based photodynamic therapy. Biochemical Pharmacology. doi:10.1016/j.bcp.2010.12.015 Peer Reviewed verified by ORBi |
Vandevenne, P., Lebrun, M., El Mjiyad, N., Ote, I., Di Valentin, E., Habraken, Y., Dortu, E., Piette, J., & Sadzot-Delvaux, C. (February 2011). The varicella-zoster virus ORF47 kinase interferes with host innate immune response by inhibiting the activation of IRF3. PLoS ONE, 9 (2). doi:10.1371/journal.pone.0016870 Peer Reviewed verified by ORBi |
Sabatel, H., Piette, J., & Habraken, Y. (25 January 2011). Role of MDC1 in NF-kappaB activation by DNA double-strand breaks [Poster presentation]. Cell Signal-OMIC, Luxembourg, Luxembourg. |
Habraken, Y., & Piette, J. (08 March 2010). NF-kappaB activation by DNA double strand breaks is MDC1 and 53BP1 dependent [Poster presentation]. Maintenance of genome stability 2010, Jolly, Antigua & Barbuda. |
Habraken, Y., & Piette, J. (27 January 2010). NF-kappaB activation by DNA double strand breaks is MDC1 and 53BP1 dependent [Poster presentation]. Inflammation 2010, Luxembourg, Luxembourg. |
Ulens, E., Sabatel, H., Piette, J., & Habraken, Y. (27 January 2010). MageD2, a newly identified ATM substrate, regulates the DNA damage induced transcriptional response [Poster presentation]. Inflammation 2010, Luxembourg, Luxembourg. |
Habraken, Y., & Piette, J. (30 March 2009). NF-kappaB activation by DNA double strand breaks is MDC1 dependent [Poster presentation]. Systems level understanding of DNA damage responses 3rd US-EU Workshop, Egmond aan Zee, Netherlands. |
Habraken, Y., & Piette, J. (08 March 2009). NF-kappaB activation by DNA double strand breaks is MDC1 and 53BP1 dependent [Poster presentation]. Maintenance of genome stability 2010, Jolly, Antigua & Barbuda. |
Habraken, Y., & Piette, J. (04 March 2008). The early nuclear steps of Nf-kappaB activation by DNA double strand breaks [Poster presentation]. Maintenance of genome stability 2008, Puerto Vallarta, Mexico. |
Mineur, P., Colige, A., Deroanne, C., Dubail, J., Kesteloot, F., Habraken, Y., Noël, A., Voo, S., Waltenberger, J., Lapière, C. M., Nusgens, B., & Lambert, C. (17 December 2007). Newly identified biologically active and proteolysis-resistant VEGF-A isoform VEGF111 is induced by genotoxic agents. Journal of Cell Biology, 179 (6), 1261-1273. doi:10.1083/jcb.200703052 Peer Reviewed verified by ORBi |
Horion, J., Gloire, G., El Mjiyad, N., Quivy, V., Vermeulen, L., Vanden Berghe, W., Haegeman, G., Van Lint, C., Piette, J., & Habraken, Y. (2007). Histone deacetylase inhibitor trichostatin A sustains sodium pervanadate-induced NF-kappa B activation by delaying IkappaBalpha mRNA resynthesis : comparison with tumor necrosis factor alpha. Journal of Biological Chemistry, 282 (21), 15383. doi:10.1074/jbc.M609166200 Peer Reviewed verified by ORBi |
Habraken, Y., & Piette, J. (30 October 2006). NF-kappa B activation by double-strand breaks [letter to the editor]. Biochemical Pharmacology, 72 (9), 1132-1141. doi:10.1016/j.bcp.2006.07.015 Peer Reviewed verified by ORBi |
Horion, J., Quivy, V., Gloire, G., Van Lint, C., Piette, J., & Habraken, Y. (23 March 2006). HDAC inhibitor trichostatin A potentiates pervanadate-induced NF-kappB activtion by delaying ikappaBalpha mRNA resynthesis [Poster presentation]. Keystone symposia NF-kappaB: 20 Years on the Road from Biochemistry to Pathology, Banff, Canada. |
Nys, M., Preiser, J.-C., Deby, G., Habraken, Y., Mathy, M., Damas, P., & Lamy, M. (2005). Nitric oxide-related products and myeloperoxidase in bronchoalveolar lavage fluids from patients with ALI activate NF-kappa B in alveolar cells and monocytes. Vascular Pharmacology, 43 (6), 425-33. doi:10.1016/j.vph.2005.08.007 Peer Reviewed verified by ORBi |
Verrax, J., Cadrobbi, J., Marques, C., Taper, H., Habraken, Y., Piette, J., & Calderon, P. B. (March 2004). Ascorbate potentiates the cytotoxicity of menadione leading to an oxidative stress that kills cancer cells by a non-apoptotic caspase-3 independent form of cell death. Apoptosis, 9 (2), 223-233. doi:10.1023/B:APPT.0000018804.26026.1a Peer Reviewed verified by ORBi |
Habraken, Y., & Piette, J. (11 January 2004). Differential involvement of the Mre11/Rad50/NBS (M/R/N) complex, BRCA1 and MLH1 in NF-kappaB activation by camptothecin and X-ray [Poster presentation]. Keystone symposia NF-kappaB : Biology and Pathology, Snowbird, United States. |
Volanti, C., Gloire, G., Vanderplasschen, A., Jacobs, N., Habraken, Y., & Piette, J. (2004). Downregulation of ICAM-1 and VCAM-1 expression in endothelial cells treated by photodynamic therapy. Oncogene, 23 (53), 8649-8658. doi:10.1038/sj.onc.1207871 Peer Reviewed verified by ORBi |
Mouithys-Mickalad, A., Deby, G., Mathy, M., Habraken, Y., Nys, M., Henrotin, Y., Lamy, M., & Deby, C. (2004). Effects of glucocorticoids on the respiratory burst of Chlamydia-primed THP-1 cells. Biochemical and Biophysical Research Communications, 318 (4), 941-8. doi:10.1016/j.bbrc.2004.04.120 Peer reviewed |
De Klerck, B., Carpentier, I., Lories, R. J., Habraken, Y., Piette, J., Carmeliet, G., Beyaert, R., Billiau, A., & Matthys, P. (2004). Enhanced osteoclast development in collagen-induced arthritis in interferon-gamma receptor knock-out mice as related to increased splenic CD11b(+) myelopoiesis. Arthritis Research and Therapy, 6 (3), 220-R231. doi:10.1186/ar1167 Peer Reviewed verified by ORBi |
Piette, J., Volanti, C., Vantieghem, A., Matroule, J.-Y., Habraken, Y., & Agostinis, P. (15 October 2003). Cell death and growth arrest in response to photodynamic therapy with membrane-bound photosensitizers. Biochemical Pharmacology, 66 (8), 1651-1659. doi:10.1016/S0006-2952(03)00539-2 Peer Reviewed verified by ORBi |
Habraken, Y., Jolois, O., & Piette, J. (04 September 2003). Differential involvement of the hMRE11/hRAD50/NBS1 complex, BRCA1 and MLH1 in NF-kappa B activation by camptothecin and X-ray. Oncogene, 22 (38), 6090-6099. doi:10.1038/sj.onc.1206893 Peer Reviewed verified by ORBi |
Nys, M., Deby, G., Habraken, Y., Legrand-Poels, S., Kohnen, S., Ledoux, D., Canivet, J.-L., Damas, P., & Lamy, M. (2003). Bronchoalveolar lavage fluids of ventilated patients with acute lung injury activate NF-kB in alveolar epithelial cell line: role of reactive oxygen/nitrogen species and cytokines. Nitric Oxide, 9 (1), 33-43. doi:10.1016/j.niox.2003.07.001 Peer Reviewed verified by ORBi |
Nys, M., Deby-Dupont, G., Habraken, Y., Legrand-Poels, S., Ledoux, D., CANIVET, J.-L., Damas, P., & Lamy, M. (December 2002). Bronchoalveolar lavage fluids of patients with lung injury activate the transcription factor nuclear factor-kappa beta in an alveolar cell line. Clinical Science, 103 (6), 577-585. doi:10.1042/cs1030577 Peer Reviewed verified by ORBi |
Habraken, Y., & Piette, J. (30 January 2002). Activation of the NF-kappaB transcription factor by Camptothecin [Poster presentation]. CELL SIGNALING, TRANSCRIPTION AND TRANSLATION AS THERAPEUTIC TARGET, Luxembourg, Luxembourg. |
Habraken, Y., & Piette, J. (07 January 2002). Activation of the NF-kappaB transcription factor by DNA damage [Poster presentation]. Molecular mechanism of DNA replication and recombination, Snowbird, United States. |
Habraken, Y., Piret, B., & Piette, J. (01 September 2001). S Phase Dependence and Involvement of Nf-Kappab Activating Kinase to Nf-Kappab Activation by Camptothecin. Biochemical Pharmacology, 62 (5), 603-16. doi:10.1016/S0006-2952(01)00709-2 Peer Reviewed verified by ORBi |
Habraken, Y., Piret, B., & Piette, J. (04 July 2001). S phase dependance and involvement of the NF-kappaB activation kinase to NF-kappaB activation by Camptotheci [Poster presentation]. International NF-kappaB symposium, Ghent, Belgium. |
Habraken, Y., Piret, B., & Piette, J. (22 February 2000). Activation of the NF-kappaB transcription factor by Camptothecin in HeLa cells [Poster presentation]. NF-kappaB Regulation and Function: From Basic Research to Drug Development (F2), Tahoe City, United States. |
Habraken, Y. (1999). DNA repair mechanisms: implication in cancer [Post doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/135380 |
Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (17 April 1998). ATP dependeny assembly of a ternary complex consisting of DNA Mismatch and the yeast Msh2-Msh6 and Mlh1-Pms1 protein complexes. Journal of Biological Chemistry, 273 (16), 9837-41. doi:10.1074/jbc.273.16.9837 Peer Reviewed verified by ORBi |
Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (01 October 1997). Enhancement of MSH2-MSH3-mediated mismatch repair recognition by the yeast MLH1-PMS1 complex. Current Biology, 7 (10), 790-3. doi:10.1016/S0960-9822(06)00337-X Peer Reviewed verified by ORBi |
Johnson, R., Kovvali, G., Guzder, S., Amin, N., Holm, C., Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (08 November 1996). Evidence of involvement of yeast proliferating cell nuclear antigen in DNA mismatch repair. Journal of Biological Chemistry, 271 (45), 27897-90. doi:10.1074/jbc.271.45.27987 Peer Reviewed verified by ORBi |
Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (01 October 1996). Transcription factor TFIIH and DNA endonuclease Rad2 constitute yeast nucleotide excision repair factor 3: implications for nucleotide excision repair and Cockayne syndrome. Proceedings of the National Academy of Sciences of the United States of America, 93 (20), 10718-22. doi:10.1073/pnas.93.20.10718 Peer Reviewed verified by ORBi |
Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (01 September 1996). Binding of insertion/deletion DNA mismatches by the heterodimer of yeast mismatch repair protein MSH2 and MSH3. Current Biology, 6 (9), 1185-7. doi:10.1016/S0960-9822(02)70686-6 Peer Reviewed verified by ORBi |
Guzder, S., Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (02 August 1996). RAD26, the yeast homolog of human Cockayne 's syndrome group B, encodes a DNA dependent ATPase. Journal of Biological Chemistry, 271 (31), 18314-7. doi:10.1074/jbc.271.31.18314 Peer Reviewed verified by ORBi |
Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (15 December 1995). Structure-specific nuclease activity in yeast nucleotide excision repair protein RAD2. Journal of Biological Chemistry, 270 (50), 30194-8. doi:10.1074/jbc.270.50.30194 Peer Reviewed verified by ORBi |
Guzder, S., Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (02 June 1995). Reconstitution of yeast nucelotide excision repair with purified RAD proteins, replication protein A and transcription factor TFIIH. Journal of Biological Chemistry, 270 (22), 12973-6. doi:10.1074/jbc.270.22.12973 Peer Reviewed verified by ORBi |
Habraken, Y., Sung, P., Prakash, L., & Prakah, S. (16 December 1994). A conserved 5' to 3' exonuclease activity in yeast and human nucleotide excision repair protein RAD2 and XPG. Journal of Biological Chemistry, 269 (50), 31342-5. Peer Reviewed verified by ORBi |
Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (06 October 1994). Holliday junction cleavage by yeast Rad1 protein. Nature, 371, 531-4. doi:10.1038/371531a0 Peer Reviewed verified by ORBi |
Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (25 August 1994). Human xeroderman group G gene encodes a DNA endonuclease. Nucleic Acids Research, 22 (16), 3312-6. doi:10.1093/nar/22.16.3312 Peer Reviewed verified by ORBi |
Habraken, Y., Sung, P., Prakash, L., & Prakash, S. (25 December 1993). Yeast excision repair RAD2 encodes a single-stranded DNA endonuclease. Nature, 366, 365-368. doi:10.1038/366365a0 Peer Reviewed verified by ORBi |
Habraken, Y., & Laval, F. (March 1993). Increased resistance of the chinese hamster mutant irs1 cells to monofunctionnal alkylating agents by transfection of the E.coli or mammalian N3-methyladenine-DNA glycosylase genes. Mutation Research, 293 (3), 187-195. doi:10.1016/0921-8777(93)90069-S Peer reviewed |
Ludlum, D., Habraken, Y., Carter, C., & Matijasevic, Z. (1992). The formation and enzymatic repair of DNA modifications caused by haloethylnitrosoureas and related compounds. Nucleic Acids Symposium Series, 105, 25-26. Peer Reviewed verified by ORBi |
Habraken, Y., & Laval, F. (15 February 1991). Enhancement of 1,3-bis(2-chloroethyl)-1-nitrosourea resistance by gy gamma-irradiation or drug pretreatment in rat hepatoma cells. Cancer Research, 51 (4), 499-503. Peer Reviewed verified by ORBi |
Habraken, Y., Carter, C., Kirk, M., & Ludlum, D. (1991). Release of 7-alkylguanines from N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea-modified DNA by 3 methyladenine DNA glycosylase. Cancer Research, 51, 499-503. Peer Reviewed verified by ORBi |
Siew, E., Habraken, Y., & Ludlum, D. (1991). Synthesis of high specificity tritium labelled chloroethylcyclohexylnitrosourea and its application to the study of DNA modification. Journal of the radiolabelled compounds and radiopharmaceuticals, XXIX, 223-230. doi:10.1002/jlcr.2580290212 Peer reviewed |
Habraken, Y., Carter, C., Sekiguchi, M., & Ludlum, D. (1991). Release of N2,3-ethanoguanine from haloethylnitrosourea-treated DNA by Escherichia coli 3-methyladenine DNA glycosylase II. Carcinogenesis, 12 (10), 1971-1973. doi:10.1093/carcin/12.10.1971 Peer Reviewed verified by ORBi |
Laval, J., Lopes, F., Madelmont, J., Godeneche, D., Meyniel, G., Habraken, Y., O'Connor, T., & Boiteux, S. (1991). Excision of imidazole ring-opened N7-hydroxyethylguanine from chloroethylnitrosourea-treated DNA by Escherichia coli formamidopyrimidine-DNA glycolsylase. IARC Scientific Publications, 105, 412-416. Peer Reviewed verified by ORBi |
Young, T. L., Habraken, Y., Ludlum, D., & Santella, R. (1990). Development of monoclonal antibodies recognizing 7-(2-hydroxyethyl)guanine and imidazole ring-opened 7-(2-hydroxyethyl)guanine. Carcinogenesis, 11, 1685-1689. doi:10.1093/carcin/11.10.1685 Peer Reviewed verified by ORBi |
Habraken, Y., Carter, C., Kirk, M., Riordan, J., & Ludlum, D. (1990). Formation of N2,3-ethanoguanine in DNA after in vitro treatment with the therapeutic agent, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea. Carcinogenesis, 11 (2), 223-228. doi:10.1093/carcin/11.2.223 Peer Reviewed verified by ORBi |
Habraken, Y., & Ludlum, D. (March 1989). Release of the chloroethyl ethyl sulfide-modified DNA bases by bacterial 3-methyladenine DNA glycosylase I and II. Carcinogenesis, 10 (3), 489-492. doi:10.1093/carcin/10.3.489 Peer Reviewed verified by ORBi |
Carter, C. A., Habraken, Y., & Ludlum, D. (30 September 1988). Release of 7-alkylguanines from haloethylnitrosourea-treated DNA by E. coli 3-methyladenine-DNA glycosylase II. Biochemical and Biophysical Research Communications, 155 (3), 1261-5. doi:10.1016/S0006-291X(88)81276-2 Peer reviewed |
Habraken, Y., & Verly, W. G. (15 January 1988). Further Purification and Characterization of the DNA 3'-Phosphatase from Rat-Liver Chromatin Which Is Also a Polynucleotide 5'-Hydroxyl Kinase. European Journal of Biochemistry, 171 (1-2), 59-66. doi:10.1111/j.1432-1033.1988.tb13758.x Peer Reviewed verified by ORBi |
Habraken, Y., & Verly, W. (24 October 1986). Chromatin 3'-phosphatase /5'OH kinase cannot transfer phosphate from 3' to 5' across a nick in DNA. Nucleic Acids Research, 14 (20), 8103-10. doi:10.1093/nar/14.20.8103 Peer Reviewed verified by ORBi |
Habraken, Y. (1986). 3' phosphatase chromatinienne et réparation des cassures produites dans l'ADN par les radiations ionisantes [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/135377 |
Habraken, Y., & Verly, W. (1984). Réparation des cassures induites par les radiations ionisantes et 3'phosphatase chromatinienne. Comptes Rendus des Séances de la Société de Biologie et de ses Filiales, 178 (2), 208-210. |
Habraken, Y., & Verly, W. (August 1983). The DNA 3'-phosphatase and 5'-hydroxyl kinase of rat liver chromatin. FEBS Letters, 160 (1,2), 46-50. doi:10.1016/0014-5793(83)80933-8 Peer Reviewed verified by ORBi |